Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors

被引:229
|
作者
Wang, Jianbin [1 ]
Exline, Colin M. [2 ]
DeClercq, Joshua J. [1 ]
Llewellyn, G. Nicholas [2 ]
Hayward, Samuel B. [1 ]
Li, Patrick Wai-Lun [1 ]
Shivak, David A. [1 ]
Surosky, Richard T. [1 ]
Gregory, Philip D. [1 ]
Holmes, Michael C. [1 ]
Cannon, Paula M. [2 ]
机构
[1] Sangamo BioSci Inc, Richmond, CA USA
[2] Univ So Calif, Keck Sch Med, Dept Mol Microbiol, Los Angeles, CA 90033 USA
基金
美国国家卫生研究院;
关键词
TARGETED GENE ADDITION; ZINC-FINGER NUCLEASES; ADENOASSOCIATED VIRUS VECTORS; STRAND BREAK REPAIR; LENTIVIRAL VECTOR; LONG-TERM; T-CELLS; IN-VIVO; DNA; CCR5;
D O I
10.1038/nbt.3408
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Genome editing with targeted nucleases and DNA donor templates homologous to the break site has proven challenging in human hematopoietic stem and progenitor cells (HSPCs), and particularly in the most primitive, long-term repopulating cell population. Here we report that combining electroporation of zinc finger nuclease (ZFN) mRNA with donor template delivery by adeno-associated virus (AAV) serotype 6 vectors directs efficient genome editing in HSPCs, achieving site-specific insertion of a GFP cassette at the CCR5 and AAVS1 loci in mobilized peripheral blood CD34(+) HSPCs at mean frequencies of 17% and 26%, respectively, and in fetal liver HSPCs at 19% and 43%, respectively. Notably, this approach modified the CD34(+)CD133(+)CD90(+) cell population, a minor component of CD34(+) cells that contains long-term repopulating hematopoietic stem cells (HSCs). Genome-edited HSPCs also engrafted in immune-deficient mice long-term, confirming that HSCs are targeted by this approach. Our results provide a strategy for more robust application of genome-editing technologies in HSPCs.
引用
收藏
页码:1256 / +
页数:10
相关论文
共 50 条
  • [41] Intracellular RNASE Activity Limits the Efficiency of mRNA-Based Gene Editing in Nonhuman Primate Hematopoietic Stem and Progenitor Cells
    Peterson, Christopher W.
    Venkataraman, Rasika
    Reddy, Sowmya S.
    Einhaus, Teresa
    Radtke, Stefan
    Humbert, Olivier
    Kiem, Hans-Peter
    MOLECULAR THERAPY, 2021, 29 (04) : 105 - 105
  • [42] Lentivector versus CRISPR/Cas9/AAV6 Gene Editing in X-Linked Severe Combined Immunodeficiency CD34+ Hematopoietic Cells
    Liu, Tayor
    Brault, Julie
    Pavel-Dinu, Mara
    Liu, Siyuan
    Meis, Ronald J.
    Koontz, Sherry
    Corsino, Cristina
    Bosticardo, Marita
    Kleinstiver, Benjamin
    Notarangelo, Luigi D.
    Wu, Xiaolin
    Dahl, Gary A.
    Porteus, Matthew
    Malech, Harry L.
    De Ravin, Suk See
    MOLECULAR THERAPY, 2020, 28 (04) : 355 - 356
  • [43] Engineering of allogeneic regulatory T cells expressing a CAR (Allo-CAR-Tregs) using ZFNmediated editing and AAV6 targeted integration
    Monteferrario, D.
    Tadi, S.
    Dupont, C.
    Jeanneau, C.
    Saviane, G.
    Marchetti, I.
    Lara, G.
    Rouquier, S.
    Ayrault, M.
    Gertner-Dardenne, J.
    de la Rosa, M.
    Fenard, D.
    HUMAN GENE THERAPY, 2022, 33 (23-24) : A142 - A143
  • [44] Targeted genome editing in mouse Hematopoietic Stem/Progenitor Cells (HSPC) to model gene correction of SCID-X1
    Schiroli, G.
    Genovese, P.
    Capo, V.
    Castiello, M. C.
    Gregory, P. D.
    Holmes, M. C.
    Sitia, G.
    Villa, A.
    Lombardo, A.
    Naldini, L.
    HUMAN GENE THERAPY, 2015, 26 (10) : A8 - A8
  • [45] Correction of SCID-X1 by Targeted Genome Editing of Hematopoietic Stem/Progenitor Cells (HSPC) in a Humanized Mouse Model
    Schiroli, Giulia
    Capo, Valentina
    Albano, Luisa
    Castiello, Maria C.
    Sanvito, Francesca
    Holmes, Michael C.
    Villa, Anna
    Sitia, Giovanni
    Lombardo, Angelo
    Genovese, Pietro
    Naldini, Luigi
    MOLECULAR THERAPY, 2017, 25 (05) : 344 - 345
  • [46] Targeted Genome Editing in Mouse Hematopoietic Stem/Progenitor Cells (HSPC) To Model Gene Correction of SCID-X1
    Schiroli, Giulia
    Genovese, Pietro
    Castiello, Maria C.
    Capo, Valentina
    Gregory, Philip D.
    Holmes, Michael C.
    Sitia, Giovanni
    Villa, Anna
    Lombardo, Angelo
    Naldini, Luigi
    MOLECULAR THERAPY, 2015, 23 : S191 - S191
  • [47] A Versatile Tool for the Quantification of CRISPR/Cas9-Induced Genome Editing Events in Human Hematopoietic Cell Lines and Hematopoietic Stem/Progenitor Cells
    Jayavaradhan, Rajeswari
    Pillis, Devin M.
    Malik, Punam
    JOURNAL OF MOLECULAR BIOLOGY, 2019, 431 (01) : 102 - 110
  • [48] Modelling Congenital Dyserythropoietic Anemia Type II in Human Hematopoietic Stem and Progenitor Cells using Gene Editing
    Dessy-Rodriguez, M.
    Fananas-Baquero, S.
    Venturi, V.
    Payan, S.
    Tornador, C.
    Hernandez, G.
    Sanchez-Fernandez, M.
    Segovia, J. C.
    Quintana-Bustamante, O.
    HUMAN GENE THERAPY, 2021, 32 (19-20) : A62 - A62
  • [49] Efficient Targeted Gene Modification in Primary Human Hematopoietic Cells Using Co-Delivery of Nuclease mRNA and AAV Donors
    Ibarra, Guillermo S. Romano
    Curinga, Gabrielle
    Sather, Blythe D.
    Sommer, Karen M.
    Hale, Malika
    Khan, Iram
    Singh, Swati
    Song, Youmei
    Gwiazda, Kamila
    Sahni, Jaya
    Khim, Socheath
    Astrakhan, Alexander
    Wagner, Thor
    Scharenberg, Andrew M.
    Rawlings, David J.
    MOLECULAR THERAPY, 2015, 23 : S273 - S273
  • [50] Engineering of Factor IX-secreting B cells using ZF-Nuclease/AAV6 editing technology in a GMP-compatible medium
    David, M.
    Monteferrario, D.
    Saviane, G.
    Jeanneau, C.
    Marchetti, I.
    Dupont, C.
    Dumont, C.
    Fontenot, J.
    De La Rosa, M.
    Fenard, D.
    HUMAN GENE THERAPY, 2022, 33 (23-24) : A59 - A59